Comparative Pharmacology
Head-to-head clinical analysis: SODIUM ROSE BENGAL I 131 versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM ROSE BENGAL I 131 versus ULTRATAG.
SODIUM ROSE BENGAL I 131 vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium rose bengal I 131 is a radioactive diagnostic agent that is taken up by hepatocytes and excreted into the bile, allowing imaging of the hepatobiliary system. The radioactive iodine (I-131) emits gamma rays, which can be detected externally to assess liver and gallbladder function.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
5-50 µCi (0.185-1.85 MBq) intravenous bolus for hepatic function imaging. For functional imaging of hepatobiliary system, typical dose: 150-300 µCi (5.55-11.1 MBq) IV.
NOT FOUND
None Documented
None Documented
Terminal elimination half-life is approximately 3-7 days, reflecting slow clearance from the liver and bile.
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Primarily hepatic excretion into bile (90-95%), with minimal renal excretion (5-10%).
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical